A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Retifanlimab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms POD1UM-304
Sponsors Incyte Corporation

07 Dec 2024 According to an Incyte media release, data presented at the European Society for Medical Oncology (ESMO) Asia Congress 2024 support the planned 2025 filing of a supplemental Biologics License Application (sBLA) in the U.S. for retifanlimab in NSCLC
07 Dec 2024 According to an Incyte media release, data from this study were presented at the European Society for Medical Oncology (ESMO) Asia Congress 2024, held in Singapore and virtually.
07 Dec 2024 Results presented in an Incyte Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com